Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ ABO Energy erhält Zuschläge für 5 weitere Windprojekte (Anleihen-Finder) +++ ABO ENERGY Aktie +3,08%

CARDIFF ONCOLOGY Aktie

 >Aktienkurs 
3.145 EUR    +3.5%    (Tradegate)
Ask: 3.25 EUR / 8000 Stück
Bid: 3.08 EUR / 11111 Stück
Tagesumsatz: 23576 Stück
Realtime Kurs von 8 bis 22 Uhr!
Aktie über LYNX handeln
>Performance
1 Woche: +17,4%
1 Monat: +4,5%
3 Monate: +20,7%
6 Monate: -30,7%
1 Jahr: +47,0%
laufendes Jahr: -24,8%
>CARDIFF ONCOLOGY Aktie
Name:  CARDIFF ONCOLOGY
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US14147L1089 / A2P4GU
Symbol/ Ticker:  XE7C (Frankfurt) / CRDF (NASDAQ)
Kürzel:  FRA:XE7C, ETR:XE7C, XE7C:GR, NASDAQ:CRDF
Index:  -
Webseite:  https://cardiffoncology.c..
Marktkapitalisierung:  224.82 Mio. EUR
Umsatz:  0.51 Mio. EUR
EBITDA:  -44.66 Mio. EUR
Gewinn je Aktie:  -0.7 EUR
Schulden:  1.17 Mio. EUR
Liquide Mittel:  69.01 Mio. EUR
Umsatz-/ Gewinnwachstum:  -46.8% / -
KGV/ KGV lG:  - / -
KUV/ KBV/ PEG:  340.68 / 3.53 / -
Gewinnm./ Eigenkapitalr.:  - / -74.15%
Dividende je Aktie:  -
Dividendenrendite/ -schätzung:  - / -
Insiderhandel:  -
Suchwörter:  CARDIFF ONCOLOGY
Letzte Datenerhebung:  03.07.25
>Eigentümer
Aktien: 66.53 Mio. St.
f.h. Aktien: 59.8 Mio. St.
Insider Eigner: 5.64%
Instit. Eigner: 45.31%
>Peer Group

 
17.06.25 - 22:54
 Cardiff Oncology falls after naming new medical chief ahead of key trial readout (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
17.06.25 - 22:09
 Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC (GlobeNewswire EN)
 
– Veteran executive with over 20 years of oncology leadership and clinical experience with proven track record of success in bringing development candidates through late-stage clinical development –...
02.06.25 - 22:09
 Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025 (GlobeNewswire EN)
 
– Results from Phase 1b clinical trial evaluating onvansertib + paclitaxel for metastatic triple negative breast cancer demonstrated 40% objective response rate –...
14.05.25 - 19:45
 Cardiff Oncology (CRDF) Upgraded to Buy: Here′s What You Should Know (Zacks)
 
Cardiff Oncology (CRDF) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy)....
08.05.25 - 23:27
 Cardiff Oncology GAAP EPS of -$0.20 misses by $0.01, revenue of $0.1M beats by $0.01M (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
15.04.25 - 22:12
 Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)
 
SAN DIEGO, April 15, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that on April 14, 2025, non-qualified stock option awards to purchase an aggregate of 35,040 shares of its common stock were granted to one new employee. The stock options were granted as inducements material to the new employee becoming an employee of Cardiff Oncology in accordance with Nasdaq Listing Rule 5635(c)(4)....
15.04.25 - 22:09
 Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer (GlobeNewswire EN)
 
- Initial results from randomized Phase 2 CRDF-004 trial in RAS-mut mCRC were released in December 2024 -...
04.03.25 - 19:45
 All You Need to Know About Cardiff Oncology (CRDF) Rating Upgrade to Buy (Zacks)
 
Cardiff Oncology (CRDF) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term....
28.02.25 - 01:45
 Cardiff Oncology (CRDF) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
 
Cardiff Oncology (CRDF) delivered earnings and revenue surprises of 16% and 11.85%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?...
27.02.25 - 22:33
 Cardiff Oncology plans mixed shelf offering (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
27.02.25 - 22:18
 Cardiff Oncology GAAP EPS of -$0.95 beats by $0.03, revenue of $0.68M beats by $0.07M (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
27.02.25 - 22:06
 Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update (GlobeNewswire EN)
 
- Robust initial efficacy signal with onvansertib + chemo/bev in ongoing first-line RAS-mut metastatic colorectal cancer (“mCRC”) clinical trial (CRDF-004) -...
20.02.25 - 22:09
 Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update (GlobeNewswire EN)
 
- Management will hold a conference call on Thursday, February 27 at 4:30 p.m. ET/1:30 p.m. PT - - Management will hold a conference call on Thursday, February 27 at 4:30 p.m. ET/1:30 p.m. PT -...
19.12.24 - 00:01
 Insiderhandel: Chief Financial Officer kauft Aktien von Cardiff Oncology im Wert von 9820 USD (Insiderkauf)
 
Levine, James E. - Vorstand - Tag der Transaktion: 2024-12-16...
19.12.24 - 00:01
 Insiderhandel: Chief Financial Officer kauft Aktien von Cardiff Oncology im Wert von 14905 USD (Insiderkauf)
 
Levine, James E. - Vorstand - Tag der Transaktion: 2024-12-17...
19.12.24 - 00:01
 Insiderhandel: Chief Financial Officer kauft Aktien von Cardiff Oncology im Wert von 12000 USD (Insiderkauf)
 
Levine, James E. - Vorstand - Tag der Transaktion: 2024-12-18...
17.12.24 - 05:01
 Insiderhandel: Aufsichtsrat kauft Aktien von Cardiff Oncology im Wert von 34224 USD (Insiderkauf)
 
Tannenbaum, Renee P. - Aufsichtsrat - Tag der Transaktion: 2024-12-12...
13.12.24 - 03:02
 Insiderhandel: Aufsichtsrat kauft Aktien von Cardiff Oncology im Wert von 940199 USD (Insiderkauf)
 
Pace, Gary W. - Aufsichtsrat - Tag der Transaktion: 2024-12-11...
11.12.24 - 17:18
 CRDF Stock Soars on Robust Efficacy Data From Colorectal Cancer Study (Zacks)
 
Cardiff Oncology stock rallies as initial data from a phase II study of onvansertib shows superior efficacy over SOC chemotherapy in colorectal cancer patients....
10.12.24 - 13:46
 Cardiff Oncology rises on positive results from mid-stage cancer study (Reuters EN)
 
BUZZ-Cardiff Oncology rises on positive results from mid-stage cancer study ** Shares of drug developer Cardiff Oncology CRDF.O rise 33.2% to $3.25 premarket ** Co announces positive initial data from its mid-stage trial testing its experimental cancer drug, onvansertib, in combination with standard-of-care treatment in patients with a type of colo...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Im Winter beim Ofen, im Sommer im Feld. - Bauernregel - Bauernweisheit
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!